RRML - Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- December 2018 -
 
Expanding PVL positive MRSA He... 8
Fungi in human pathology - are... 7
Platelets and Infections... 6
FLT-3 ITD Positive Acute Basop... 5
Phenotypic and molecular ident... 5
Multiplex ligation dependent p... 5
Romanian Review of Laboratory ... 4
Detection of anti-protease inh... 4
The flow cytometric labeling p... 3
Complete blood count and diffe... 3

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 26(4)/2018 DOI:10.2478/rrlm-2018-0029
XML
TXT

Research article

Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania

Sorin Dinu, Grațiela Țârdei, Emanoil Ceaușu, Simin Aysel Florescu, Laurențiu Micu, Alina Monica Ecobici, Mariana Mihăilă, Gabriela Oprișan

Correspondence should be addressed to: Sorin Dinu

Abstract:

Background: Severe complications of chronic hepatitis C – i.e. cirrhosis and hepatocellular carcinoma – are important causes of morbidity and mortality worldwide. Despite the overwhelming rates of sustained virologic response achieved after therapy with different combinations of direct-acting antiviral drugs (DAAs), treatment failure is still recorded, and is due to the mutations harboured by hepatitis C virus (HCV) resistance associated variants (RAVs) selected during therapy. Baseline RAVs testing was found significant for guiding treatment in the cases of treatment failure and, sometimes, in naïve patients. Methods: Romanian chronic hepatitis C patients unexposed to DAAs and infected with subtype 1b HCV were studied. Serum samples were used for Sanger population sequencing of a fragment containing NS3 viral protease, known to harbour resistance mutation against protease inhibitors (PIs). Results: Catalytic triad and zinc-binding site in the studied sequences were conserved. Low-intermediate resistance mutations to first generation PIs were detected either alone or in conjunction with resistance substitutions associated with second generation PIs. Cross-resistance and reduced susceptibility to certain DAAs were observed. Discussion: This study focused on HCV patients infected with subtype 1b strains, the most prevalent in Romania. The rate of RAVs found in this work is consistent with the results reported by similar studies from other countries. Noticeably, numerous polymorphisms of unknown significance to DAAs resistance, but reflecting the high genetic variability of HCV, were found in the studied sequences. Testing for RAVs can be a useful method for guiding treatment in a cost-efficient manner in developing countries where access to DAAs is limited.

Keywords: NS3 protease, direct-acting antivirals, resistance mutations, naïve to treatment patients

Received: 21.5.2018
Accepted: 10.7.2018
Published: 8.8.2018

 
  PDF Download full text PDF
(347 KB)
     
 
How to cite
Dinu S, Țârdei G, Ceaușu E, Florescu SA, Micu L, Ecobici AM, et al. Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania. Rev Romana Med Lab. 2018;26(4):443-9. DOI:10.2478/rrlm-2018-0029